HALO on Nasdaq

Halozyme Therapeutics

Logo: halozyme.com3

American biological products company based in San Diego, founded in 1998.1

Price unavailable

Last updated Oct 18, 2026.

Overview

1998Founded1

Compare with Bio-Techne, Novavax or Moderna, or pick any stock.

  • TickerHALO on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego1
  • Websitewww.Halozyme.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address12390 El Camino Real, San Diego, Ca 921304
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

33.6%Operating margin5
22.7%Net margin5
37.6%Revenue growth, 20255
649.2%Return on equity5
43.89×Debt to equity5
$644.6MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Royalty brought in 62% of the revenue Halozyme Therapeutics broke down this way in fiscal 2025.

  1. Royalty$867.8M562%up 52% from 2024
  2. Proprietary Products Sales$194.6M514%up 17% from 2024
  3. Bulk rHuPH20$133.0M510%up 54% from 2024
  4. Sales-based milestone$70.0M55%up 133% from 2024
  5. Device Partnered Products$48.8M53%down 3% from 2024
  6. Event -based Development And Regulatory Milestone And Other Fees$47.0M53%down 35% from 2024
  7. Upfront Fees$18.5M51%down 32% from 2024
  8. Device Licensing and Development$16.9M51%up 49% from 2024
Products and services by year
Products and services202320242025
Royalty$447.9M$571.0M$867.8M
Proprietary Products Sales$130.8M$166.6M$194.6M
Bulk rHuPH20$115.4M$86.3M$133.0M
Sales-based milestone$0$30.0M$70.0M
Device Partnered Products$54.6M$50.5M$48.8M
Event -based Development And Regulatory Milestone And Other Fees$69.0M$72.5M$47.0M
Upfront Fees$2.0M$27.0M$18.5M
Device Licensing and Development$9.5M$11.3M$16.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue16¢$228.8M
  • Selling, general and admin15¢$207.1M
  • Other costs35¢$493.9M
  • Income tax11¢$150.0M
  • Profit23¢$316.9M

Out of $1.4B in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending1¢$7.0M
  • Share buybacks53¢$342.4M
  • Kept or used elsewhere46¢$302.2M

Out of $651.6M of cash from operations.5

Financial statements

Revenue67895$1.4B in 2025+613% since 2019
0$500.0M$1.0B$1.5B2019: $196.0M$196.0M20192020: $267.6M$267.6M2020+37%2021: $443.3M$443.3M2021+66%2022: $660.1M$660.1M2022+49%2023: $829.3M$829.3M2023+26%2024: $1.0B$1.0B2024+22%2025: $1.4B$1.4B2025+38%
Operating income67895$469.0M in 2025
-$200.0M0$200.0M$400.0M$600.0M2019: -$67.6M-$67.6M20192020: $144.3M$144.3M20202021: $275.9M$275.9M2021+91%2022: $267.5M$267.5M2022−3%2023: $337.6M$337.6M2023+26%2024: $551.5M$551.5M2024+63%2025: $469.0M$469.0M2025−15%
Net income67895$316.9M in 2025
-$200.0M0$200.0M$400.0M$600.0M2019: -$72.2M-$72.2M20192020: $129.1M$129.1M20202021: $402.7M$402.7M2021+212%2022: $202.1M$202.1M2022−50%2023: $281.6M$281.6M2023+39%2024: $444.1M$444.1M2024+58%2025: $316.9M$316.9M2025−29%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenues$1.4B$1.0B$829.3M
Cost of sales$228.8M$159.4M$192.4M
Amortization of intangibles$76.7M$71.0M$73.8M
Research and development$81.5M$79.0M$76.4M
Selling, general and administrative$207.1M$154.3M$149.2M
Impairment of intangible asset$48.7M$0$0
Acquired in-process research and development expense$284.9M$0$0
Total operating expenses$927.6M$463.8M$491.7M
Operating income$469.0M$551.5M$337.6M
Investment and other income, net$21.5M$23.8M$16.3M
Inducement expense related to convertible notes-$5.5M$0$0
Contingent liability fair value measurement gain$0$0$13.2M
Interest expense-$18.1M-$18.1M-$18.8M
Income before income tax expense$466.9M$557.1M$348.3M
Income tax expense$150.0M$113.0M$66.7M
Net income$316.9M$444.1M$281.6M
Basic (usd per share)$2.64$3.50$2.13
Diluted (usd per share)$2.56$3.43$2.10
Basic (in shares)119.8M shares126.8M shares131.9M shares
Diluted (in shares)123.9M shares129.4M shares134.2M shares

Compare Halozyme Therapeutics with another company

Leadership

Who has led Halozyme Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jonathan E. Lim2007–2010
  2. Gregory Ian Frost2011–2013
  3. Helen Torley2014–now

President

  1. Jonathan E. Lim2007–2009
  2. Gregory Ian Frost2011–2013
  3. Helen Torley2014–now

Chief financial officer

  1. David A. Ramsay2007–2010
  2. Kurt A. Gustafson2010–2013
  3. Laurie Stelzer2015–2020
  4. Elaine D. Sun2020–2021
  5. Nicole Labrosse2022–2026
  6. Darren Snellgrove2026–now

Chief operating officer

  1. Mark J. Gergen2016–2017
  2. Cortney Caudill2025–now
200020052010201520202025
Board members and other officers (38)

Former names

  • HALOZYME THERAPEUTICS INCMar 17, 2004 to Jul 3, 20194
  • GLOBAL YACHT SERVICES INCSep 21, 2001 to Mar 12, 20044

Timeline

  1. Jan 8, 2014New chief executive Helen Torley becomes CEO14
  2. May 6, 2011New chief executive Gregory Ian Frost becomes CEO15
  3. Feb 7, 2007New chief executive Jonathan E. Lim becomes CEO16
  4. 1998Founded Founded1

Filings

427 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 70 major events, 214 insider forms, 20 large holders, 103 other. The latest 20:

  1. Oct 8, 20264 EDGAR
  2. Oct 8, 20264/A EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20263 EDGAR
  5. Oct 2, 20264 EDGAR
  6. Sep 30, 20268-K EDGAR
  7. Sep 22, 20268-K EDGAR
  8. Sep 18, 20268-K EDGAR
  9. Sep 17, 20264 EDGAR
  10. Sep 16, 2026144 EDGAR
  11. Sep 16, 20268-K EDGAR
  12. Sep 11, 20264 EDGAR
  13. Sep 2, 20264 EDGAR
  14. Aug 21, 20263 EDGAR
  15. Aug 19, 20264 EDGAR
  16. Aug 18, 20268-K EDGAR
  17. Aug 17, 2026144 EDGAR
  18. Aug 11, 2026144 EDGAR
  19. Aug 11, 20264 EDGAR
  20. Aug 10, 2026144 EDGAR

The 427 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 20 such filings since October 2021, the latest 10:

  1. Apr 30, 2026SCHEDULE 13G
  2. Mar 27, 2026SCHEDULE 13G/A
  3. May 13, 2025SCHEDULE 13G
  4. Nov 12, 2024SC 13G/A
  5. Oct 17, 2024SC 13G
  6. Feb 13, 2024SC 13G/A
  7. Feb 12, 2024SC 13G/A
  8. Feb 1, 2024SC 13G/A
  9. Jan 23, 2024SC 13G/A
  10. Jun 9, 2023SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.13,271,095$1.0B0.0%+6,042
Vanguard Capital Management LLC5,351,312$418.8M0.0%+80,094
Vanguard Portfolio Management LLC5,299,008$414.8M0.0%+49,802
State Street Corp5,179,434$405.4M0.0%+241,580
Invesco Ltd.3,177,997$248.7M0.0%−834,497
Morgan Stanley2,832,594$221.7M0.0%+270,285
Boston Partners2,773,568$216.8M0.2%+89,885
Bank Of America Corp /de/2,740,561$214.5M0.0%−172,548
Geode Capital Management, LLC2,519,951$197.3M0.0%+14,165
William Blair Investment Management, LLC2,511,050$196.5M0.6%−14,925
Snyder Capital Management L P2,396,101$187.5M3.2%+73,024
Dimensional Fund Advisors LP2,089,567$163.5M0.0%+9,740
D. E. Shaw & Co., Inc.2,006,479$157.0M0.1%+137,771
Assenagon Asset Management S.A.1,995,286$156.2M0.1%+1,973,964
Los Angeles Capital Management LLC1,938,035$151.7M0.6%+1,248,120
Royal London Asset Management Ltd1,810,815$141.7M0.3%+200,262
Arrowstreet Capital, Limited Partnership1,704,623$133.4M0.1%−213,526
Two Sigma Investments, LP1,653,285$129.4M0.1%+68,324
UBS Group AG1,492,224$116.8M0.0%+578,221
Fuller & Thaler Asset Management, Inc.1,491,004$116.7M0.3%+25,721
Norges Bank1,483,648$116.1M0.0%New
First Trust Advisors LP1,417,063$110.9M0.1%−65,277
Alliancebernstein L.P.1,696,538$109.6M0.0%−39,963
Stephens Investment Management Group LLC1,392,819$109.0M1.2%+174,151
Wells Fargo & Company/mn1,390,428$108.8M0.0%−145,309

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

10 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000−7.9%Report
Mar 9, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+64.5%Report
Mar 24, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000−55.4%Report
Sep 9, 2024Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000−63.9%Report
Jul 12, 2023Daniel S. GoldmanDemocratic, HouseSale$15,001 - $50,000−153.7%Report
Dec 6, 2022Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000−19.5%Report
Aug 5, 2022Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000−82.6%Report
Aug 20, 2021Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000+133.2%Report
Oct 22, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+166.9%Report
Oct 19, 2020Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000+186.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59